genebridges.com
News - GeneBridges
http://www.genebridges.com/news
Add the advantages of recombineering to the power of CRISPR/Cas9 to extend your genome studies. Add the advantages of recombineering to the power of CRISPR/Cas9 to extend your genome studies. Follow our latest publication on Lentiviral plasmid generation. 2016 Gene Bridges GmbH. Please choose your country. If the country is missing, continue.
genebridges.com
Recombineering - GeneBridges
http://www.genebridges.com/recombineering
Add the advantages of recombineering to the power of CRISPR/Cas9 to extend your genome studies. Nation-mediated genetic engi neerin. And specifies a well-defined and precise modification of DNA. This outstanding technology was developed by the group of A. Francis Stewart at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany in the late 1990s. Gene Bridges’ Red/ET recombination technique is an in vivo. Reaction and is based either on the red. Genes of phage lambda or the rec. Examples...
genebridges.com
Sitemap - GeneBridges
http://www.genebridges.com/sitemap
Add the advantages of recombineering to the power of CRISPR/Cas9 to extend your genome studies. Constructs for animal models. 2016 Gene Bridges GmbH. Please choose your country. If the country is missing, continue.
genebridges.com
Distributors - GeneBridges
http://www.genebridges.com/distributors
Add the advantages of recombineering to the power of CRISPR/Cas9 to extend your genome studies. 2016 Gene Bridges GmbH. Please choose your country. If the country is missing, continue.
visualprotein.com
Distributor
http://www.visualprotein.com/vispro/index.php/distributor-list
UNITED KINGDOM / IRELAND. Evolve Life Sciences Pty Ltd. Website: www.evolvelifesciences.com. Mail: This email address is being protected from spambots. You need JavaScript enabled to view it. Website: www.gentaur.com. Mail: This email address is being protected from spambots. You need JavaScript enabled to view it. Website: www.divbio.nl. Mail: This email address is being protected from spambots. You need JavaScript enabled to view it. Website: www.valquim.cl. Website: www.mirbiotech.com. Website: www...
genebridges.com
Collaborations - GeneBridges
http://www.genebridges.com/collaborations
Add the advantages of recombineering to the power of CRISPR/Cas9 to extend your genome studies. Please contact us if you are interested in a collaboration and developing innovative ideas together with us: contact@genebridges.com. 2016 Gene Bridges GmbH. Please choose your country. If the country is missing, continue.
genebridges.com
Company - GeneBridges
http://www.genebridges.com/company
Add the advantages of recombineering to the power of CRISPR/Cas9 to extend your genome studies. The team consists of highly skilled technicians and scientists with profound knowledge of molecular and microbiological techniques, mouse genetics, transgene strategies, biochemistry, metabolic engineering and industrial biotechnology. 2016 Gene Bridges GmbH. Please choose your country. If the country is missing, continue.
genebridges.com
Licenses - GeneBridges
http://www.genebridges.com/licenses
Add the advantages of recombineering to the power of CRISPR/Cas9 to extend your genome studies. Gene Bridges GmbH owns the exclusive rights to Red/ET Recombination, a revolutionary DNA engineering technology. Gene Bridges issues licenses for the use of the Red/ET Recombination technology to commercial users. Licensing arrangements for Red/ET Recombination are provided as world-wide, non-exclusive sub-licenses. For more information please contact licenses@genebridges.com. 2016 Gene Bridges GmbH.
genebridges.com
Publications - GeneBridges
http://www.genebridges.com/references-publications
Add the advantages of recombineering to the power of CRISPR/Cas9 to extend your genome studies. Ambrogio C, Stern P, Scuoppo C, Kranz H, Barbacid M and Santamaría D, 2014. Lentiviral-based approach for the validation of cancer therapeutic targets in vivo, BioTechniques, 57, 179. Vaisman A, McDonald JP, Noll S, Huston D, Loeb G, Goodmann MF and Woodgate R, 2014. Investigating the mechanisms of ribonucleotide excision repair in Escherichia coli. Mutation Res, 761, 21. BL21(DE3), Biospektrum, 19, 211. Effic...